{"id":669931,"date":"2023-09-27T17:14:01","date_gmt":"2023-09-27T17:14:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=669931"},"modified":"2023-09-27T17:14:01","modified_gmt":"2023-09-27T17:14:01","slug":"gastroenteropancreatic-neuroendocrine-tumors-market-anticipates-impressive-growth-trajectory-through-2032-asserts-delveinsight-novartis-ipsen-pfizer-experior-tarveda-roche-exelixis-bayer","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/gastroenteropancreatic-neuroendocrine-tumors-market-anticipates-impressive-growth-trajectory-through-2032-asserts-delveinsight-novartis-ipsen-pfizer-experior-tarveda-roche-exelixis-bayer_669931.html","title":{"rendered":"Gastroenteropancreatic Neuroendocrine Tumors Market Anticipates Impressive Growth Trajectory Through 2032 – Asserts DelveInsight | Novartis, Ipsen, Pfizer, Experior, Tarveda, Roche, Exelixis, Bayer"},"content":{"rendered":"
\n
\"Gastroenteropancreatic<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the Gastroenteropancreatic Neuroendocrine Tumors Market is anticipated to evolve immensely in the coming years owing to the increase in the patient pool and expected entry of emerging therapies in the market.<\/div>\n

DelveInsight’s “Gastroenteropancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Gastroenteropancreatic Neuroendocrine Tumors market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging Gastroenteropancreatic Neuroendocrine Tumors drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Gastroenteropancreatic Neuroendocrine Tumors treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

Gastroenteropancreatic Neuroendocrine Tumors: An Overview<\/strong><\/p>\n

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are tumors that arise from neuroendocrine cells in the gut. These cells release hormones that control various functions of the digestive system. The symptoms of GEP-NETs depend on where the tumor is growing in the gut and whether it produces excess hormones. By the time of diagnosis, the tumors have spread to other organs such as the liver.<\/p>\n

GEP-NETs are debilitating as they often produce excess hormones that may cause severe symptoms. They are life-threatening if they spread to other organs in the body.<\/p>\n

The World Health Organization (WHO) 2010 and 2017 classification system categorizes GEP-NETs into three grades based on histological differentiation and cell proliferation index, which guides treatment decisions. Tumor grade is determined by the highest number of either Ki-67 protein or mitotic count, and it offers an important prognostic value for GEP-NETs. In 2017, the WHO updated the staging classifications for pancreatic NETs (pNETs) to recognize well-differentiated grade 3 tumors, allowing for more precisely targeted treatment options for Grade III tumors.<\/p>\n

Poorly differentiated grade 3 pNETs may continue to be treated with standard systemic chemotherapy, whereas well- and moderately differentiated grade 3 pNETs have been shown to benefit from targeted therapies (everolimus or sunitinib). Well-differentiated pNETs may even benefit from surgery.<\/p>\n

Gastroenteropancreatic Neuroendocrine Tumors Market Key Facts<\/strong><\/p>\n